Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae

J. M. Blondeau, X. Zhao, G. Hansen, K. Drlica

Research output: Contribution to journalArticlepeer-review

287 Scopus citations

Abstract

The mutant prevention concentration (MPC) represents a threshold above which the selective proliferation of resistant mutants is expected to occur only rarely. A provisional MPC (MPCpr) was defined and measured for five fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Based on their potential for restricting the selection of resistant mutants, the five fluoroquinolones, in descending order, were found to be moxifloxacin > trovafloxacin > gatifloxacin > grepafloxacin > levofloxacin. For several compounds, 90% of about 90 clinical isolates that lacked a known resistance mutation had a value of MPCpr that was close to or below the serum levels that could be attained with a dosing regimen recommended by the manufacturers. Since MPCpr overestimates MPC, these data identify moxifloxacin and gatifloxacin as good candidates for determining whether MPCpr can be used as a guide for choosing and eventually administering fluoroquinolones to significantly reduce the development of resistance.

Original languageEnglish (US)
Pages (from-to)433-438
Number of pages6
JournalAntimicrobial agents and chemotherapy
Volume45
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae'. Together they form a unique fingerprint.

Cite this